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ABSTRACT 
Background:  Cardiac risk stratification and coronary angiography are routinely performed as 
part of kidney and liver transplant candidacy evaluation.  There are limited data on the outcomes 
of surgical coronary revascularization in this patient population.  We investigated outcomes in 
patients with end stage renal or hepatic disease undergoing coronary artery bypass grafting 
(CABG) to attain kidney or liver transplant candidacy.  
Methods:  Retrospective analysis of all patients who underwent isolated CABG at our institution 
between 2010 and 2016.  Patients were divided into two cohorts:  Pre-transplant (those 
undergoing surgery to attain renal or hepatic transplant candidacy) and Non-transplant (all 
others).  Baseline characteristics and postoperative outcomes were compared between groups. 
Results:  A total of 1801 patients were included:  28 in Pre-transplant (n=22 kidney, n=7 liver) 
and 1773 in Non-transplant.  Major adverse postoperative outcomes were significantly greater in 
Pre-transplant compared to Non-transplant:  30-day mortality (14.3% vs. 2.8%, p=0.009), 
neurologic events (17.9% vs. 4.8%, p=0.011), re-intubation (21.4% vs. 5.8%, p=0.005) and total 
postoperative ventilation (5.2 vs. 5.0 hours, p=0.0124).  One- and five-year mortality in Pre-
transplant was 17.9% and 53.6%, respectively.  Of the Pre-transplant cohort, three patients 
(10.7%) underwent organ transplantation (all kidneys) at a mean 436 days after CABG.  No 
patients received liver transplantation.   
Conclusions:  Outcomes following CABG in the pre-kidney and pre-liver transplant population 
are poor.  Despite surgical revascularization, the vast majority of patients do not ultimately 
undergo transplantation.  Revascularization strategies and optimal management in this high-risk 
population warrants further study.  
  
  
Coronary artery disease (CAD) is highly prevalent among patients with end-stage kidney 
or liver disease.  Studies indicate that over 70% of patients on hemodialysis (HD) have some 
form of cardiovascular disease (CVD), with 40% to 81% having CAD.1-8  Up to 26% of patients 
awaiting orthotopic liver transplantation (OLT) have CAD.2, 3 Moreover, the leading cause of 
death pre- and post-transplantation is CVD, especially within the early post-transplantation 
period.2, 4-6  
Despite the survival benefit of solid abdominal organ transplantation, matched donors 
remain scarce.8  Consequently, cardiac risk stratification is an integral part of the candidacy 
evaluation of potential organ recipients.  However, there remains controversy in (1) the proper 
guidelines to follow,9-13 (2) the utility of noninvasive tests like dobutamine-stress 
echocardiography (DSE) and myocardial perfusion studies (MPS) to screen for clinically 
significant CAD,14-16 (3) angiographically significant coronary lesions,5, 17, 18 and (4) the efficacy 
of coronary revascularization in improving outcomes and transplant candidacy.19-23  Despite such 
ambiguity, patients found to have CAD are routinely referred for coronary revascularization 
before being cleared for transplant eligibility.   
Isolated coronary artery bypass grafting (CABG) outcomes are among the most heavily 
studied, with recent Society of Thoracic Surgeons (STS) data indicating overall mortality 
approaching less than 2%.24 Yet, there are few published results describing outcomes in patients 
who undergo CABG in order to attain abdominal organ transplant candidacy.  Moreover, the 
likelihood of a patient ultimately receiving the desired organ transplant after CABG is unknown.  
Our institution is a high-volume renal and hepatic transplantation center, and we sought to 
investigate CABG outcomes in this population.  To our knowledge, this study is the first to 
examine the incidence of the desired organ transplantation after undergoing CABG to achieve 
candidacy. 
 
MATERIAL AND METHODS 
The Institutional Review Board of Indiana University approved this retrospective study.  
An institutional STS database was queried to identify all patients who underwent isolated CABG 
at our institution between 2010 and 2016.  Data were extracted from this registry and from 
individual medical records.  Patients who underwent CABG in order to achieve abdominal organ 
transplant candidacy were identified by a separate query of each individual medical record for 
the term “transplant” followed by a manual confirmatory review of each chart.  The study cohort 
was then divided into two groups:  “Pre-transplant” (those undergoing surgery to achieve liver or 
kidney transplant candidacy) and “Non-transplant” (all others). 
In addition, a state-wide medical registry (Regenstrief Institute, Indianapolis, IN) was 
utilized to assess post-CABG outcomes of the Pre-transplant group such as transplant status and 
survival. This allowed data capture even if a patient sought medical attention outside our 
institution, as long as the care was obtained within Indiana.  Primary outcomes studied were 30-
day mortality and incidence of desired solid abdominal organ transplantation after CABG.  
Secondary outcomes included postoperative variables including length of stay (LOS), 
mechanical ventilation time, blood product usage, stroke, pneumonia, readmission, reintubation, 
and time to transplantation.  Pre-transplant and Non-transplant groups were compared.  A 
secondary subset analysis was then conducted comparing Pre-transplant end stage renal disease 
(ESRD) patients and Non-transplant patients with ESRD. 
 
Statistical Methods  
 Descriptive analysis was performed to examine the distribution of patient characteristics 
and postoperative outcomes in the sample groups using frequency distribution for categorical 
variables and median (Interquartile Range) for continuous variables.  Bivariate analyses were 
completed to investigate the outcomes of Pre-transplant compared to Non-transplant using 
Fisher’s exact test and Wilcoxon rank-sum test for categorical and continuous variables, 
respectively. Thirty-day survival analysis was performed using log-rank test to determine the 
difference between Pre-transplant and Non-transplant and was displayed using Kaplan-Meier 
plots. The Hazard ratio (HR) [95% CI] was also reported using bivariate Cox proportional hazard 
methods to estimate the relative risk of mortality among Pre-transplant patients compared to 
Non-transplant after verifying the proportionality of hazards assumption. Significant difference 
between groups was assessed using a type I error rate of 0.05. All analyses were performed using 
Stata SE/14.2 (StataCorp, L.P., College Station, TX).  
RESULTS 
A total of 1801 patients were included in the study.  Baseline demographic and 
preoperative characteristics are listed in Table 1 for Pre-transplant (n=28) and Non-transplant 
(n=1773).  Pre-transplant consisted of 22 patients with ESRD and 6 patients with end-stage liver 
disease (ESLD).  Of these, one patient had combined ESRD-ESLD.  Non-transplant was 
comprised of all other CABG patients.  All Pre-transplant ESRD patients were dialysis-
dependent, while the median Model for End-Stage Liver Disease (MELD) score in Pre-transplant 
ESLD was 10.49 (IQR 8.72) (Table 2). 
For the entire cohort, median age was 63 years (IQR 14.0) and 72.8% were male.  
Diabetes, renal failure/dialysis, and liver disease were significantly more common in Pre-
transplant.  Unstable angina or acute coronary syndrome were significantly more common in 
Non-transplant, while the majority of Pre-transplant patients were asymptomatic or had stable 
angina (Table 1).  71.4% of Pre-transplant cases were classified as Elective, 28.6% were Urgent, 
and none were Emergent.  In Non-transplant, 49.1% were Elective, 46.6% Urgent, and 4.3% 
Emergent.   
Postoperative 30-day mortality was significantly different between Pre-transplant and 
Non-transplant (14.3% and 2.8%, respectively, p=0.009) (Table 3 and Figure 1).  For Pre-
transplant, the predicted 30-day mortality based on the STS risk calculator was 5.1%.  The 
incidence of receiving the desired abdominal organ transplant during the entire follow-up period 
was low:  of all Pre-transplant patients, three (10.7%) underwent renal transplant (all were 
deceased donor kidneys) and none underwent liver transplant.  The three renal transplants 
occurred at 337, 426, and 544 days following CABG.  Of the seven Pre-transplant ESLD 
patients, one had post-CABG complications (sepsis, new onset dialysis-dependent renal failure,  
gastrostomy tube-dependent) which precluded transplant eligibility, two recovered liver function 
after successful medical treatment of hepatitis C (HCV), one was lost to follow-up, and three 
died during the follow-up period. 
Other postoperative outcomes were also notably different between Pre-transplant and 
Non-transplant, with Pre-transplant having significantly worse outcomes for essentially all 
secondary outcome measures except for sepsis and 30-day readmission (Table 3).   
A subset analysis was performed to compare between Pre-transplant ESRD patients (all 
dialysis-dependent) with Non-transplant ESRD dialysis-dependent patients.  Baseline 
characteristics were not different between these two groups (Table 4).  Of Pre-transplant ESRD, 
52.4% were on hemodialysis and 47.6% on peritoneal dialysis, with the mean duration on 
dialysis of 34.7 months.  This data was not available for the Non-transplant ESRD group.  Acute 
coronary syndrome or unstable angina were more common in Non-transplant ESRD, while 
45.5% of Pre-transplant ESRD were asymptomatic.  Postoperative outcomes including 30-day 
mortality and postoperative adverse events were similar between the two (Table 4).   
 
COMMENT 
Current literature on coronary revascularization to attain abdominal organ transplant 
candidacy yields conflicting results regarding outcomes and survival.20-23,25,26  Retrospective 
reviews by Felix et al. and Patel and colleagues reported no survival advantage of 
revascularization by percutaneous coronary intervention (PCI) or CABG prior to abdominal 
organ transplantation over coronary angiography without intervention.27,28  On the other hand, 
Maddur et al. showed that PCI revascularization led to improved outcomes after OLT, while 
Kumar and associates found that coronary revascularization while awaiting organ transplant 
improved 1- and 3-year survival.25,28  
Our results from the present study indicate that CABG in patients undergoing candidacy 
evaluation for renal or hepatic transplantation have poor outcomes.  Our institutional protocol is 
to thoroughly review these patients in a combined cardiology-cardiac surgery “Heart Team” 
conference before proceeding with surgical revascularization.  Nonetheless, these patients had 
short-term mortality of 14.3%, which far exceeded that predicted by the STS risk calculator, and 
had 5 times greater mortality than all other isolated CABG patients combined.  Both Pre-
transplant ESRD and ESLD patients had similar 30-day mortality, underscoring the inherent 
high-risk of all such patients with end-stage organ disease.  Intermediate- and long- term 
outcomes were similarly poor, with 1- and 5- year all-cause mortality of 17.9% and 53.6%, 
respectively.  It is feasible that the intermediate- and long- term deaths are due to either 
underlying kidney or liver disease, or due to intrinsic cardiac disease.  The exact cause of death 
beyond 30-days was not available and could not be verified for this study.  
We further analyzed Pre-transplant ESRD patients by comparing this group to Non-
transplant dialysis-dependent ESRD patients. As expected, these two groups were similar in all 
characteristics except for presenting status, with more asymptomatic patients in Pre-transplant 
and more acute coronary syndrome patients in Non-transplant.  30-day mortality was greater in 
the Pre-transplant group (9% vs. 5%, p=0.711) although this was not statistically significant.  All 
other postoperative outcomes were also similar.  This subgroup analysis suggests that perhaps 
the poor outcomes in Pre-transplant ESRD may be a consequence of the underlying renal disease 
itself rather than being attributable to renal transplant candidacy per se.  
Results of the study’s other primary outcome--the incidence of desired organ 
transplantation after CABG--are also remarkable, and, quite frankly, unexpected.  Pre-transplant 
patients underwent CABG in order to attain transplant eligibility, but the majority died within 5 
years of surgery without receiving the desired organ.  Our institution is a major abdominal organ 
transplant center, with leading volumes of kidney and, in particular, liver, transplantation.  Yet, 
we found that only three (10%) of the Pre-transplant patients ultimately received the desired 
organ after CABG:  all were deceased donor kidney transplants, which occurred at 11 months, 14 
months, and 18 months after CABG.  These wait times were relatively short, given that the 
median wait time for a kidney transplant is 45.4 months at our institution and 50.3 months 
nationally.7  The reason for this low transplant rate is unclear; unfortunately, it was not possible 
to ascertain retrospectively whether/when patients were “listed” and whether donor kidneys were 
offered and not accepted.  These data points could aid future decision making on whether to offer 
CABG.  We surmise that the value of performing high-risk CABG could be justified if a patient 
is likely to become actively placed on the waiting list, but perhaps less so if predicted transplant 
eligibility likelihood is low.  While this could be mitigated by performing CABG only after a 
patient is “listed,” at present most centers (including ours) do not place patients on a waiting list 
until known CAD is treated.   
None of the Pre-transplant ESLD patients underwent transplantation over the 5-year 
follow-up period.  This is particularly surprising given our institution’s relatively short wait time 
for OLT (median 2.1 months vs. 10.7 months nationally).7  Of the Pre-transplant ESLD patients, 
three had documented reasons that precluded transplant eligibility.  The remainder survived 
CABG beyond 30-days but did not undergo OLT for unknown reasons.  These patients did not  
have any notable incidence of pulmonary hypertension or heart failure, which in some cases may 
benefit from combined heart-liver transplant (not offered at our institution) albeit with more 
difficult donor-recipient matching due to the need for two simultaneous organs. 
For both ESRD and ESLD, one explanation for the low transplantation rate could be that 
the patients underwent CABG at a very early stage of the candidacy evaluation process before 
even rough estimates of eligibility could be assessed.  If the cardiac evaluation were performed 
after other components of the candidacy screening process, patients with low likelihood of 
attaining candidacy would already be excluded and thus not referred for coronary 
revascularization. With this approach, the two ESLD patients in our study who recovered after 
medical management of HCV, for example, would likely have been referred for revascularization 
after being deemed not transplant candidates due to hepatic recovery.  Without overt ESLD, 
these patients could then have undergone much lower-risk CABG instead.  We could not 
accurately identify, for purposes of this study, where in the transplant candidacy evaluation 
process each patient was at the time of referral for CAD.  Obtaining this information may be 
beneficial for future prospective studies. 
Interestingly, the MELD score for the Pre-transplant ESRD group was higher (19.7) than 
that for ESLD (10.5).  This is explained by the fact that the ESRD patients were dialysis-
dependent and had elevated creatinine values, both of which result in a high MELD score even in 
the absence of defined liver disease. On the other hand, the ESLD group MELD was relatively 
low (although 25% of all patients eligible for OLT at our institution have MELD score between 6 
and 14) because our general practice, with Heart Team discussion, is to refrain from offering 
CABG in patients with MELD > 15 in the setting of intrinsic hepatic disease.  In other words, 
ESLD patients with MELD > 15 referred for CAD evaluation would have been declined for 
CABG and offered PCI instead, and thus would not be included in the present study.  We do, 
however, regularly perform CABG in patients with MELD > 15 if we suspect the elevated score 
is primarily due to renal dysfunction (hence the higher MELD score in the Pre-transplant ESRD 
group).  A future study examining the treatment decision and outcomes of ESLD patients with 
MELD > 15 who were referred for revascularization as part of a transplant candidacy evaluation 
would shed light on this particular population. 
Pre-transplant patients also had significantly higher post-CABG morbidity than Non-
transplant in nearly all secondary outcomes studied.  Postoperative complications were more 
frequent in Pre-transplant than Non-transplant by almost all metrics, again highlighting the high-
risk associated with these underlying co-morbidities. 
Given the high prevalence of cardiovascular disease and CAD in ESRD and ESLD 
patients, pre-transplant cardiac assessment is justified.  Yet, the need for routine coronary 
angiography and revascularization for the sake of achieving transplant candidacy remains 
unclear.1,5,9,13  Some of this ambiguity may be due to poor reliability of non-invasive testing such 
as DSE and MPS in this particular patient population.15,17,29  While the American Heart 
Association and American College of Cardiology do not recommend non-invasive testing for 
non-cardiac surgery in asymptomatic patients with good functional capacity even in the presence 
of certain risk factors, because of the high incidence of significant CAD in pre-transplant 
patients, many centers, including ours, have traditionally performed angiography in these 
patients.5,9,10  However, the definition of clinically significant disease in this group may differ 
from the general population.5,30  Perhaps intervention in the pre-transplant population should be 
reserved for patients with certain clinical and angiographic characteristics (critical left main 
disease, for instance), especially in asymptomatic patients.18  A more targeted approach deserves 
further study.  
Some have posed convincing arguments in favor of abandoning screening altogether for 
asymptomatic kidney transplant candidates since receiving a kidney transplant in and of itself 
lowers long-term cardiovascular-related mortality.13 Because ESRD and ESLD patients are 
inherently higher risk for CABG, one proposal could be that only those with a greater likelihood 
of ultimately receiving the desired transplant should undergo surgery.  In other words, as our 
study shows, if the chances of receiving the desired transplant are exceedingly low at our center, 
then should we be subjecting these patients to high-risk CABG?  One proposal could be that 
these patients must be discussed in conjunction with the Heart Team and the transplant 
evaluation team together so that a holistic picture of eligibility likelihood and stage of candidacy 
assessment can be considered.  
Perhaps the most significant limitation of this study is inherent to its design as a single-
center, retrospective study with low sample size.  We tried to mitigate this by utilizing multiple 
databases, including a statewide registry that captures patient data from care obtained outside our 
institution.  It is certainly possible that some Pre-transplant patients chose to transfer care to 
another state, which we would not be able to capture in this study.  The low sample size was 
simply a function of the relatively rare nature of this particular patient population.  The inclusion 
dates were maximized to capture all available patients within the existing data registries. 
An international randomized controlled trial addressing this topic of CAD in pre-
transplant patients is already underway (Canadian-Australasian randomized trial of screening 
kidney transplants, or CARSK) in which transplant candidates on the wait list are randomized to 
no CAD screening versus current screening and intervention protocols.13,31  We anticipate this 
study to shed valuable data on the utility of preemptive coronary revascularization.  Future 
studies could further delineate the appropriate role of CABG in this patient population with 
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Table 1. Patient characteristics by study group 
Characteristic Non-Transplant 
(n=1,773) 
Pre-Transplant                
(n=28) 
p-value 
Age, years 63(14) 63(5) 0.4520 
Gender   >0.999 
Male 1,290(72.76) 21(75.00)  
Female 483(27.24) 7(25.00)  
Body Mass Index   0.219 
Underweight 18(1.02) 1(3.57)  
Normal 289(16.30) 7 (25.00)  
Overweight 613(34.57) 8(28.57)  
Obese 853(48.11) 12(42.86)  
Chronic Lung Disease   0.475 
Mild  284(16.02) 8(28.57)  
Moderate 126(7.11) 1(3.57)  
Severe 70 (3.95) 1 (3.95)  
Unknown 25(1.41) 0  
Diabetes 918(51.78) 23 (82.14) 0.002 
Hypertension 1,606(90.58) 27 (96.43) 0.509 
Immunocompromised 92(5.19) 4 (14.29) 0.058 
Dialysis-dependent 61(3.44) 22(78.57) <0.0001 
Cerebrovascular Disease 284(16.02) 9(32.14) 0.050 
Liver Disease 63(4.65) 8(33.33) <0.0001 
Tobacco Use   0.118 
Never 712(40.16) 14(50.00)  
Current 380(21.43) 3(10.71)  
Former 240(13.54) 7(25.00)  
Last Creatinine, mg/dL 1(0.38) 4.73(3.98) <0.0001 











































Categorical data presented as number(%) unless otherwise indicated. Continuous data 
presented as Median(Interquartile Range). MELD, model for end-stage liver disease; STEMI, 



















Table 2. Postoperative outcomes by study group 
Postoperative Outcome Non-Transplant 
(n=1,773) 
Pre-Transplant                
(n=28) 
p-value 
30-Day Mortality 50(2.82) 4 (14.29) 0.009 
Length of Stay, days 6(3) 8(6.5) 0.0008 
Total Ventilation, hours 4(5) 5.19(17.44) 0.0124 
Surgical Site Infection 17(0.96) 2(7.14) 0.058 
In-Hospital Postoperative Events 650(36.66) 16(57.14) 0.026 
Neurologic 85(4.79) 5(17.86) 0.011 
Pneumonia 76(4.29) 5(17.86) 0.035 
Sepsis 21(1.18) 0 >0.999 
Cardiac Arrest 43(2.43) 4(14.29) 0.021 
Blood Product Transfusion 618(34.86) 18 (64.29) 0.001 
Re-intubation 103(5.81) 6 (21.43) 0.005 
30-day Readmission  44(2.48) 2(7.14) 0.164 
Categorical data presented as number(%) unless otherwise indicated. Continuous data 













Table 3. Patient characteristics and postoperative outcomes by Pre-transplant organ 
failure group 














Diabetes 19(86.36) 5(71.43) 
Hypertension 21(95.45) 7(100) 
Dialysis-dependent  22(100.0) 1(14.29) 
Ejection Fraction, % 47.7(13.99) 49.7(9.44) 
Cerebrovascular Disease  8(36.36) 1(14.29)  
Immunocompromised 3(13.64) 1(14.29) 
Liver Disease  
Viral Hepatitis (HCV)  
Non-alcoholic steatohepatitis  
Autoimmune hepatitis  











Pulmonary Hypertension (>moderate) 2(9.09) 0 







































Postoperative Outcomes    
30-Day Mortality 3(13.6) 1(14.29) 
Length of Stay, days 8(5) 9(19) 
Total Ventilation, hours 5(18.3) 8.18(16.95) 
Surgical Site Infection 1(7.14) 1(20.0) 
In-Hospital Postoperative Events 12(54.55) 5(71.43) 
Neurologic 4(18.18) 1(14.29) 
Pneumonia 4(33.33) 1(20.0) 
Sepsis 0 0 
Cardiac Arrest 4(33.3) 0 
Blood Product Transfusion 15(68.18) 3(42.86) 
Re-intubation 5(22.73) 1(14.29) 
30-day Readmission  2(9.09) 0 
Categorical data presented as number(%) unless otherwise indicated. Continuous data 
presented as Median(Interquartile Range). ESRD, end-stage renal disease; ESLD, end-stage 
liver disease; HCV, hepatitis C virus; MELD, model for end-stage liver disease; UA, unstable 











Table 4. Patient characteristics and postoperative outcomes of dialysis-dependent patients 








Age, years 63(11) 63.5(6) 0.7255 
Gender   0.310 
Male 40(65.57) 17(77.27)  
Female 21(34.43) 5(22.73)  
Body Mass Index 27.97(7.42) 30.29(4.07) 0.3169 
Chronic Lung Disease 24(39.34) 6(27.27) 0.312 
Cerebrovascular Disease 11(18.03) 8(36.36) 0.079 
Hypertension 58(95.08) 21(95.45) >0.999 
Diabetes  46(75.41) 19(86.36) 0.374 
Last Creatinine, mg/dL 5(3.6) 5.85(3.6) 0.3611 














Presentation   <0.0001 
UA/Non-STEMI 40(65.57) 4(18.18)  
STEMI 3(4.92) 0  
Stable Angina 8(13.11) 3(13.64)  
Asymptomatic 10(16.39) 15(45.45)  
Postoperative Outcomes    
30-day Mortality  3(4.92) 2(9.09) 0.711 
Length of Stay, days 7.29(9) 11.75(8) 0.3924 
Total Ventilation, hours 5.87(12.13) 5(18.3) 0.6082 
Surgical Site Infection 2(3.28) 1(4.55) >0.999 
In-Hospital Postoperative Events 29(47.54) 12(54.55) 0.573 
Neurologic 3(4.92) 4(18.18) 0.076 
Pneumonia 5(8.20) 4(18.18) 0.236 
Sepsis 0 0  
Cardiac Arrest 4(6.56) 4(18.18) 0.073 
Blood Product Transfusion 37(60.66) 15(68.18) 0.532 
Reintubation 8(13.11) 5(22.73) 0.288 
30-day Readmission 11(18.03) 4(18.18) >0.999 
Categorical data presented as number(%) unless otherwise indicated. Continuous data 
presented as Median(Interquartile Range). ESRD, end-stage renal disease; UA, unstable angina; 


















Figure 1. 30-day survival after CABG by study group 

